Serum Trace Elements Profile in Graves’ Disease Patients with or without Orbitopathy in Northeast China

Table 1

Demographics characteristics and thyroid parameters in different groups.

Variables	NC ()	EUGD ()	HyGD ()	GO ()
Age (years)
Gender (F/M)	48/18	48/7	49/17	41/16
BMI (kg/m^2)
TSH (mIU/L)	1.84 (1.16–2.90)	1.45 (0.24–2.41)	0.01 (0.00–0.02)	2.19 (0.82–3.66)
FT3 (pmol/L)	4.46 (4.14–4.76)	4.81 (4.29–5.24)	14.39 (7.55–30.52)	4.35 (3.74–4.83)
FT4 (pmol/L)	12.88 (11.97–13.81)	12.44 (11.15–14.12)	21.89 (15.84–35.98)	12.68 (11.11–14.12)
TPOAb (IU/mL)	0.38 (0.13–1.07)	56.72 (8.87–223.00)	109.75 (18.21–447.38)	19.46 (0.13–203.48)
TgAb (IU/mL)	1.24 (0.92–3.85)	82.00 (27.09–209.70)	97.01 (18.49–367.50)	4.23 (1.22–33.96)
TRAb (IU/mL)	-	2.05 (1.24–6.72)	12.25 (5.30–21.02)	5.98 (1.65–15.36)

EUGD: subjects with stable euthyroid status or subclinical hyperthyroidism after treatment who used to have Graves’ disease; HyGD: newly diagnosed Graves’ disease patients; GO: Graves’ ophthalmopathy patients with euthyroid state or subclinical hyperthyroidism after treatment with antithyroid drugs; NC: normal controls. are expressed as mean ± SD. are expressed as medians (interquartile range); versus NC, versus NC, and versus EUGD; “-”: did not detect; TSH, thyroid stimulating hormone; FT3, free T3; FT4, free T4; TPOAb, thyroperoxidase antibody; TgAb, antithyroglobulin antibody; TRAb, TSH receptor autoantibody.